Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


Articles published in Int J Hematol

Retrieve available abstracts of 157 articles:
HTML format



Single Articles


    September 2022
  1. UMEZAWA Y, Sasaki K
    Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia.
    Int J Hematol. 2022 Sep 10. pii: 10.1007/s12185-022-03431.
    PubMed     Abstract available


  2. SUN H, Yan Z, Zhang S
    Three atypical BCR/ABL transcripts detected simultaneously in a Philadelphia-positive acute lymphoblastic leukemia patient showing resistance to tyrosine kinase inhibitors.
    Int J Hematol. 2022 Sep 10. pii: 10.1007/s12185-022-03451.
    PubMed     Abstract available


  3. HIROSAWA M, Goto M, Oku M, Akao K, et al
    Mogamulizumab for post-transplant relapse of adult T-cell leukemia/lymphoma: a case study.
    Int J Hematol. 2022 Sep 9. pii: 10.1007/s12185-022-03447.
    PubMed     Abstract available


  4. NARLI OZDEMIR Z, Kilicaslan NA, Yilmaz M, Eskazan AE, et al
    Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities.
    Int J Hematol. 2022 Sep 5. pii: 10.1007/s12185-022-03446.
    PubMed     Abstract available


  5. MAGNOLI F, Casiccia L, Ripamonti F, Uccella S, et al
    Simultaneous diagnosis of plasma cell myeloma and chronic lymphocytic leukemia on bone marrow trephine biopsy.
    Int J Hematol. 2022 Sep 2. pii: 10.1007/s12185-022-03443.
    PubMed    


  6. BIAVASCO F, Zeiser R
    FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2022;116:341-350.
    PubMed     Abstract available


    August 2022
  7. HAN L, Li Y, Wu J, Peng J, et al
    Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
    Int J Hematol. 2022 Aug 28. pii: 10.1007/s12185-022-03441.
    PubMed     Abstract available


  8. HOSHINO T, Hatsumi N, Iino H, Takada S, et al
    Therapy-related myeloid neoplasms of recipient origin after allogeneic hematopoietic stem cell transplantation for acute leukemia.
    Int J Hematol. 2022 Aug 28. pii: 10.1007/s12185-022-03442.
    PubMed     Abstract available


  9. SUZUMIYA J, Takizawa J
    Correction to: Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Int J Hematol. 2022 Aug 27. pii: 10.1007/s12185-022-03439.
    PubMed    


  10. ONO T, Hino M, Matsumura I, Fujisawa S, et al
    Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
    Int J Hematol. 2022 Aug 13. pii: 10.1007/s12185-022-03435.
    PubMed     Abstract available


  11. AYDIN S, Passera R, Scaldaferri M, Dellacasa CM, et al
    Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
    Int J Hematol. 2022 Aug 9. pii: 10.1007/s12185-022-03427.
    PubMed     Abstract available


  12. TSUDA M, Hirata A, Tokunaga S, Masuda T, et al
    Rapid decrease in eGFR with concomitant use of tyrosine kinase inhibitors and renin-aldosterone-angiotensin system inhibitors in patients with chronic myelogenous leukemia.
    Int J Hematol. 2022 Aug 6. pii: 10.1007/s12185-022-03433.
    PubMed     Abstract available


  13. LAGANA A, Scalzulli E, Carmosino I, Martelli M, et al
    Asciminib as a third line option in chronic myeloid leukemia.
    Int J Hematol. 2022 Aug 5. pii: 10.1007/s12185-022-03432.
    PubMed     Abstract available


    July 2022
  14. HIRADE K, Kusumoto S, Abe A, Noritake H, et al
    A novel RARA-SNX15 fusion in PML-RARA-positive acute promyelocytic leukemia with t(11;17;15)(q13;q21.2;q24.1).
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03421.
    PubMed     Abstract available


  15. HAGINO T, Sato T, Saga R, Hidai H, et al
    Myeloid leukemoid reaction after initial azacitidine therapy for chronic myelomonocytic leukemia.
    Int J Hematol. 2022 Jul 19. pii: 10.1007/s12185-022-03422.
    PubMed     Abstract available


  16. CHEN X, Liu L, Zhang A, Yi M, et al
    Droplet digital PCR for genetic mutations monitoring predicts relapse risk in pediatric acute myeloid leukemia.
    Int J Hematol. 2022 Jul 18. pii: 10.1007/s12185-022-03402.
    PubMed     Abstract available


  17. KREIDIEH F, Abou Dalle I, Moukalled N, El-Cheikh J, et al
    Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment.
    Int J Hematol. 2022 Jul 16. pii: 10.1007/s12185-022-03416.
    PubMed     Abstract available


  18. MIYAJIMA T, Hasegawa Y, Hashimoto D, Teshima T, et al
    Unilateral recurrent laryngeal nerve palsy detected by PET/CT in a patient with mediastinal T-cell lymphoblastic lymphoma.
    Int J Hematol. 2022;116:3-4.
    PubMed    


  19. YOSHIDA C, Kondo T, Ito T, Kizaki M, et al
    Real-world treatment patterns and clinical outcomes in patients with AML in Japan who were ineligible for first-line intensive chemotherapy.
    Int J Hematol. 2022;116:89-101.
    PubMed     Abstract available


  20. HE J, Liu J, Shen H, Wang Z, et al
    Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
    Int J Hematol. 2022;116:71-80.
    PubMed     Abstract available


    June 2022
  21. CAO XY, Li JJ, Lu PH, Liu KY, et al
    Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2022 Jun 23. pii: 10.1007/s12185-022-03398.
    PubMed     Abstract available


  22. MATSUOKA A, Tanibuchi M, Yamazaki I, Taoka T, et al
    Erythroblast predominance without CD41/cyCD41-positive blasts predicts favorable prognosis in patients with myelodysplastic syndromes and acute myeloid leukemias treated with azacitidine.
    Int J Hematol. 2022;115:852-859.
    PubMed     Abstract available


  23. KAWAKAMI F, Kawakami T, Yamane T, Maruyama M, et al
    T cell clonal expansion and STAT3 mutations: a characteristic feature of acquired chronic T cell-mediated pure red cell aplasia.
    Int J Hematol. 2022;115:816-825.
    PubMed     Abstract available


  24. ONISHI Y, Onodera K, Fukuhara N, Kato H, et al
    Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.
    Int J Hematol. 2022;115:873-881.
    PubMed     Abstract available


  25. WATANABE N, Takaku T, Tsukune Y, Yasuda H, et al
    Bosutinib-induced lung injury: a report of two cases and literature review.
    Int J Hematol. 2022;115:902-905.
    PubMed     Abstract available


    May 2022
  26. NAKAYAMA H, Ogawa C, Sekimizu M, Fujisaki H, et al
    A phase I study of inotuzumab ozogamicin as a single agent in pediatric patients in Japan with relapsed/refractory CD22-positive acute lymphoblastic leukemia (INO-Ped-ALL-1).
    Int J Hematol. 2022 May 30. pii: 10.1007/s12185-022-03388.
    PubMed     Abstract available


  27. CAPRIA S, Trisolini SM, Diverio D, Minotti C, et al
    Autologous stem cell transplantation in favorable-risk acute myeloid leukemia: single-center experience and current challenges.
    Int J Hematol. 2022 May 13. pii: 10.1007/s12185-022-03370.
    PubMed     Abstract available


  28. MIZUTA S, Ugai T, Kato H, Doki N, et al
    Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
    Int J Hematol. 2022 May 10. pii: 10.1007/s12185-022-03368.
    PubMed     Abstract available


  29. TACHIBANA T, Tanaka M, Hagihara M, Fujimaki K, et al
    Outcomes in patients with acute lymphoblastic leukemia who underwent second allogeneic hematopoietic cell transplantation for relapse after first transplantation.
    Int J Hematol. 2022 May 9. pii: 10.1007/s12185-022-03377.
    PubMed     Abstract available


  30. ARAI Y, Chi S, Minami Y, Yanada M, et al
    FLT3-targeted treatment for acute myeloid leukemia.
    Int J Hematol. 2022 May 9. pii: 10.1007/s12185-022-03374.
    PubMed     Abstract available


  31. NGUYEN TTT, Tamai M, Harama D, Kagami K, et al
    Introduction of the T315I gatekeeper mutation of BCR/ABL1 into a Philadelphia chromosome-positive lymphoid leukemia cell line using the CRISPR/Cas9 system.
    Int J Hematol. 2022 May 6. pii: 10.1007/s12185-022-03369.
    PubMed     Abstract available


  32. FUKUYAMA T, Kitamura T, Kozu T
    UBC9 inhibits myeloid differentiation in collaboration with AML1-MTG8.
    Int J Hematol. 2022;115:686-693.
    PubMed     Abstract available


  33. LU N, Lin J, Wang LL, Li YY, et al
    A retrospective single-center analysis of G-CSF-mobilized donor lymphocyte infusion in hematologic malignancies after unmanipulated allogenic PBSCT.
    Int J Hematol. 2022;115:713-727.
    PubMed     Abstract available


    April 2022
  34. SOBIERALSKI P, Bieniaszewska M, Leszczynska A, Zuk M, et al
    Secondary chronic myeloid leukemia in a patient with CALR and ASXL1-mutated primary myelofibrosis.
    Int J Hematol. 2022 Apr 16. pii: 10.1007/s12185-022-03331.
    PubMed     Abstract available


  35. HAYAKAWA J, Nakasone H, Minakata D, Fujiwara SI, et al
    Comparison of the impact of two post-remission therapy regimens on cardiac events in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2022 Apr 16. pii: 10.1007/s12185-022-03343.
    PubMed     Abstract available


  36. MARUMO A, Wakita S, Morita K, Oh I, et al
    NPM1-mutation-based measurable residual disease assessment after completion of two courses of post-remission therapy is a valuable clinical predictor of the prognosis of acute myeloid leukemia.
    Int J Hematol. 2022 Apr 4. pii: 10.1007/s12185-022-03328.
    PubMed     Abstract available


    March 2022
  37. KODAMA Y, Sato A, Kato K, Sakaguchi H, et al
    Ponatinib in pediatric patients with Philadelphia chromosome-positive leukemia: a retrospective survey of the Japan Children's Cancer Group.
    Int J Hematol. 2022 Mar 29. pii: 10.1007/s12185-022-03329.
    PubMed     Abstract available


  38. TASHIRO Y, Kanda J, Iemura T, Kondo T, et al
    Feasibility of ovarian stimulation for fertility preservation during and after blinatumomab treatment for Ph-negative B-cell acute lymphoblastic leukemia.
    Int J Hematol. 2022 Mar 14. pii: 10.1007/s12185-022-03323.
    PubMed     Abstract available


  39. TAKAHASHI Y, Ishida H, Imamura T, Tamefusa K, et al
    JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
    Int J Hematol. 2022 Mar 8. pii: 10.1007/s12185-022-03315.
    PubMed     Abstract available


  40. TAKAHASHI N, Cortes JE, Sakaida E, Ishizawa K, et al
    Safety profile of bosutinib in Japanese versus non-Japanese patients with chronic myeloid leukemia: a pooled analysis.
    Int J Hematol. 2022 Mar 2. pii: 10.1007/s12185-022-03314.
    PubMed     Abstract available


  41. ADACHI Y, Sakai T, Terakura S, Shiina T, et al
    Downregulation of HLA class II is associated with relapse after allogeneic stem cell transplantation and alters recognition by antigen-specific T cells.
    Int J Hematol. 2022;115:371-381.
    PubMed     Abstract available


    February 2022
  42. KOJIMA H, Nakayama H, Kosugi N
    Bilateral adrenal hemorrhage: a rare presentation of acute myeloid leukemia.
    Int J Hematol. 2022 Feb 25. pii: 10.1007/s12185-022-03316.
    PubMed    


  43. HWANG WL, Chen TC, Lin HY, Chang MC, et al
    NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan.
    Int J Hematol. 2022 Feb 25. pii: 10.1007/s12185-022-03311.
    PubMed     Abstract available


  44. IIDA H, Imada K, Ueda Y, Kubo K, et al
    A phase II randomized study evaluating azacitidine versus conventional care regimens in newly diagnosed elderly Japanese patients with unfavorable acute myeloid leukemia.
    Int J Hematol. 2022 Feb 24. pii: 10.1007/s12185-022-03307.
    PubMed     Abstract available


  45. CHENG S, Xiao P, Wang J, Li Z, et al
    Decitabine combined with minimally myelosuppressive therapy for induction of remission in pediatric high-risk acute myeloid leukemia with chromosome 5q deletion: a report of three cases.
    Int J Hematol. 2022 Feb 18. pii: 10.1007/s12185-022-03309.
    PubMed     Abstract available


  46. SATO S, Tamai Y
    Acute monocytic leukemia with histiocytic morphology in hematological remission after azacytidine and venetoclax therapy.
    Int J Hematol. 2022 Feb 8. pii: 10.1007/s12185-022-03296.
    PubMed    


  47. MORI A, Onozawa M, Hidaka D, Yokoyama S, et al
    Non-age-related neoplastic loss of sex chromosome correlated with prolonged survival in real-world CBF-AML patients.
    Int J Hematol. 2022;115:188-197.
    PubMed     Abstract available


  48. SAWADA A, Shimizu M, Koyama-Sato M, Higuchi K, et al
    Radiation-sparing reduced-intensity unrelated umbilical cord blood transplantation for rare hematological disorders in children.
    Int J Hematol. 2022;115:269-277.
    PubMed     Abstract available


  49. WEI X, Zhuang J, Li N, Zheng B, et al
    NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
    Int J Hematol. 2022;115:278-286.
    PubMed     Abstract available


    January 2022
  50. HIGUCHI K, Sawada A, Kondo O, Okada Y, et al
    HLA-haploidentical peripheral blood stem cell transplantation following reduced-intensity conditioning with very low-dose antithymocyte globulin for relapsed/refractory acute leukemia in pediatric patients: a single-institution retrospective analysis.
    Int J Hematol. 2022 Jan 14. pii: 10.1007/s12185-021-03270.
    PubMed     Abstract available


  51. AKAHOSHI Y, Nakasone H, Kusuda M, Kameda K, et al
    Emergence of clone with PHF6 nonsense mutation in chronic myelomonocytic leukemia at relapse after allogeneic HCT.
    Int J Hematol. 2022 Jan 6. pii: 10.1007/s12185-021-03284.
    PubMed     Abstract available


  52. BABA M, Imamura M, Imai C
    Newly diagnosed ETV6-RUNX1-positive B-acute lymphoblastic leukemia localized to the left pelvic bone marrow.
    Int J Hematol. 2022 Jan 4. pii: 10.1007/s12185-021-03269.
    PubMed    


  53. GOMEZ-CENTURION I, Oarbeascoa G, Garcia MC, Lopez Fresnena MC, et al
    Implementation of a hospital-at-home (HAH) unit for hematological patients during the COVID-19 pandemic: safety and feasibility.
    Int J Hematol. 2022;115:61-68.
    PubMed     Abstract available


    December 2021
  54. OHWADA C, Yamazaki S, Shono K, Kayamori K, et al
    Pharmacokinetically guided, once-daily intravenous busulfan in combination with fludarabine for elderly AML/MDS patients as a conditioning regimen for allogeneic stem cell transplantation.
    Int J Hematol. 2021;114:664-673.
    PubMed     Abstract available


    November 2021
  55. KOBAYASHI S, Sano H, Mochizuki K, Ohara Y, et al
    Effects of second transplantation with T-cell-replete haploidentical graft using low-dose anti-thymocyte globulin on long-term overall survival in pediatric patients with relapse of leukemia after first allogeneic transplantation.
    Int J Hematol. 2021 Nov 25. pii: 10.1007/s12185-021-03266.
    PubMed     Abstract available


  56. NAKAMAE M, Nakamae H, Hashimoto M, Koh H, et al
    Predictive value of clinical examination parameters for cardiovascular adverse events during treatment of chronic myeloid leukemia with tyrosine kinase inhibitors.
    Int J Hematol. 2021 Nov 17. pii: 10.1007/s12185-021-03259.
    PubMed     Abstract available


  57. WANG X, Diamond DJ, Forman SJ, Nakamura R, et al
    Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine.
    Int J Hematol. 2021;114:544-553.
    PubMed     Abstract available


    October 2021
  58. HONDA Y, Muramatsu H, Nanjo Y, Hirabayashi S, et al
    A retrospective analysis of azacitidine treatment for juvenile myelomonocytic leukemia.
    Int J Hematol. 2021 Oct 29. pii: 10.1007/s12185-021-03248.
    PubMed     Abstract available


  59. INOUE Y, Nishimura N, Murai M, Matsumoto M, et al
    Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2021 Oct 27. pii: 10.1007/s12185-021-03250.
    PubMed     Abstract available


  60. SHIBATA S, Inano S, Watanabe M, Fujiwara K, et al
    Identification of an asymptomatic Shwachman-Bodian-Diamond syndrome mutation in a patient with acute myeloid leukemia.
    Int J Hematol. 2021 Oct 26. pii: 10.1007/s12185-021-03251.
    PubMed     Abstract available


  61. IKAWA Y, Takenaka M, Sakai Y, Noguchi K, et al
    Utility of 18F-FDG-PET for detecting acute lymphoblastic leukemia: a case series of pediatric acute lymphoblastic leukemia without hematological symptoms.
    Int J Hematol. 2021 Oct 13. pii: 10.1007/s12185-021-03232.
    PubMed     Abstract available


  62. NUKUI J, Tanaka M, Nakajima H
    A case of multiple brain abscesses due to Bacillus cereus during induction therapy for acute myeloid leukemia.
    Int J Hematol. 2021 Oct 7. pii: 10.1007/s12185-021-03226.
    PubMed    


  63. LEE SH, Yoon JH, Min GJ, Park SS, et al
    Response to blinatumomab or inotuzumab ozogamicin for isolated extramedullary relapse of adult acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation: a case study.
    Int J Hematol. 2021 Oct 6. pii: 10.1007/s12185-021-03231.
    PubMed     Abstract available


  64. KAWANO N, Kimura S, Miura M, Tochigi T, et al
    Serial evaluation of the pharmacokinetics of ponatinib in patients with CML and Ph + ALL.
    Int J Hematol. 2021;114:509-516.
    PubMed     Abstract available


    September 2021
  65. DEMBITZ V, Lalic H, Tomic B, Smoljo T, et al
    All-trans retinoic acid induces differentiation in primary acute myeloid leukemia blasts carrying an inversion of chromosome 16.
    Int J Hematol. 2021 Sep 21. pii: 10.1007/s12185-021-03224.
    PubMed     Abstract available


  66. NAKAMAE H, Yamamoto M, Sakaida E, Kanda Y, et al
    Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: 10-year followup of the Japanese subgroup of the randomized ENESTnd trial.
    Int J Hematol. 2021 Sep 11. pii: 10.1007/s12185-021-03216.
    PubMed     Abstract available


  67. IZUMI A, Tachibana T, Ando T, Tanaka M, et al
    A case series of patients treated with inotuzumab ozogamicin for acute lymphoblastic leukemia relapsed after allogeneic hematopoietic cell transplantation.
    Int J Hematol. 2021 Sep 6. pii: 10.1007/s12185-021-03217.
    PubMed     Abstract available


    August 2021
  68. HAN W, Zhou F, Wang Z, Hua H, et al
    Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
    Int J Hematol. 2021 Aug 27. pii: 10.1007/s12185-021-03210.
    PubMed     Abstract available


    July 2021
  69. KAKO S, Hayakawa F, Imai K, Tanaka J, et al
    Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
    Int J Hematol. 2021 Jul 30. pii: 10.1007/s12185-021-03198.
    PubMed     Abstract available


  70. SATOH T, Kayano H, Watanabe A, Ohta A, et al
    Lethal macrophage-related complications of juvenile myelomonocytic leukemia with a blastic crisis: an autopsy case report.
    Int J Hematol. 2021 Jul 16. pii: 10.1007/s12185-021-03189.
    PubMed     Abstract available


    June 2021
  71. LV K, Cai C, Chen J, Xu M, et al
    Prognostic value of lymphoid marker CD7 expression in acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplantation in first morphological complete remission.
    Int J Hematol. 2021 Jun 26. pii: 10.1007/s12185-021-03182.
    PubMed     Abstract available


  72. MORI T, Kikuchi T, Yamazaki R, Koda Y, et al
    Phase 1 study of plerixafor in combination with total body irradiation-based myeloablative conditioning for allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2021;113:877-883.
    PubMed     Abstract available


    May 2021
  73. ARAKAWA Y, Masutani S, Oshima K, Mitani Y, et al
    Asian population may have a lower incidence of hip osteonecrosis in childhood acute lymphoblastic leukemia.
    Int J Hematol. 2021 May 18. pii: 10.1007/s12185-021-03163.
    PubMed     Abstract available


  74. MORITA K, Sasaki K
    Current status and novel strategy of CML.
    Int J Hematol. 2021;113:624-631.
    PubMed     Abstract available


  75. KIMURA S
    Evolution of CML treatment.
    Int J Hematol. 2021;113:622-623.
    PubMed    


  76. SHAN M, Lu Y, Yang M, Wang P, et al
    Characteristics and transplant outcome of myeloid sarcoma: a single-institute study.
    Int J Hematol. 2021;113:682-692.
    PubMed     Abstract available


    April 2021
  77. KIDOGUCHI K, Ureshino H, Kizuka-Sano H, Yamaguchi K, et al
    Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute.
    Int J Hematol. 2021 Apr 27. pii: 10.1007/s12185-021-03156.
    PubMed     Abstract available


  78. CHUAH C, Koh LP, Numbenjapon T, Zang DY, et al
    Efficacy and safety of bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia in the Asian subpopulation of the phase 3 BFORE trial.
    Int J Hematol. 2021 Apr 13. pii: 10.1007/s12185-021-03144.
    PubMed     Abstract available


  79. KOBAYASHI T, Ubukawa K, Fujishima M, Takahashi N, et al
    Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis.
    Int J Hematol. 2021;113:600-605.
    PubMed     Abstract available


    March 2021
  80. KONDO H, Kanayama T, Matsumura U, Urata T, et al
    Relapsed RUNX1-RUNX1T1-positive acute myeloid leukemia with pseudo-Chediak-Higashi granules.
    Int J Hematol. 2021 Mar 29. pii: 10.1007/s12185-021-03141.
    PubMed    


  81. BNAYA A, Ruchlemer R, Itzkowitz E, Gabbay E, et al
    Incidence, risk factors, and recognition of pseudohyperkalemia in patients with chronic lymphocytic leukemia.
    Int J Hematol. 2021 Mar 29. pii: 10.1007/s12185-021-03142.
    PubMed     Abstract available


  82. LEE H, Basso IN, Kim DDH
    Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia.
    Int J Hematol. 2021 Mar 27. pii: 10.1007/s12185-021-03126.
    PubMed     Abstract available


  83. NAKANO N, Takatsuka Y, Kubota A, Tokunaga M, et al
    Correction to: Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2021 Mar 17. pii: 10.1007/s12185-021-03125.
    PubMed    


  84. MORISHIGE S, Miyamoto T, Eto T, Uchida N, et al
    Clinical features and chromosomal/genetic aberration in adult acute lymphoblastic leukemia in Japan: results of Fukuoka Blood & Marrow Transplant Group Studies ALL MRD 2002 and 2008.
    Int J Hematol. 2021 Mar 16. pii: 10.1007/s12185-021-03116.
    PubMed     Abstract available


  85. JUNG J, Lee E, Shim H, Park JH, et al
    Prediction of clinical outcomes through assessment of sarcopenia and adipopenia using computed tomography in adult patients with acute myeloid leukemia.
    Int J Hematol. 2021 Mar 10. pii: 10.1007/s12185-021-03122.
    PubMed     Abstract available


  86. NAKA K
    New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism.
    Int J Hematol. 2021 Mar 5. pii: 10.1007/s12185-021-03112.
    PubMed     Abstract available


  87. CHOI EJ, Lee JH, Kim H, Choi Y, et al
    Autologous hematopoietic cell transplantation following high-dose cytarabine consolidation for core-binding factor-acute myeloid leukemia in first complete remission: a phase 2 prospective trial.
    Int J Hematol. 2021 Mar 2. pii: 10.1007/s12185-021-03099.
    PubMed     Abstract available


  88. URESHINO H
    Treatment-free remission and immunity in chronic myeloid leukemia.
    Int J Hematol. 2021 Mar 2. pii: 10.1007/s12185-021-03117.
    PubMed     Abstract available


    February 2021
  89. ISHIDA H, Yano M, Hasegawa D, Hori T, et al
    Prednisolone poor response is not an indication for HSCT in pediatric B-cell precursor acute lymphoblastic leukemia in first remission: results from JACLS ALL-02 study.
    Int J Hematol. 2021 Feb 28. pii: 10.1007/s12185-021-03110.
    PubMed     Abstract available


  90. TERAKURA S, Kuwatsuka Y, Sugita J, Takahashi S, et al
    Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
    Int J Hematol. 2021 Feb 21. pii: 10.1007/s12185-021-03097.
    PubMed     Abstract available


  91. NAKANO N, Takatsuka Y, Kubota A, Tokunaga M, et al
    Cord blood transplantation with a reduced-intensity conditioning regimen using fludarabine and melphalan for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2021 Feb 16. pii: 10.1007/s12185-021-03102.
    PubMed     Abstract available


  92. AKAHOSHI Y, Arai Y, Nishiwaki S, Mizuta S, et al
    Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Int J Hematol. 2021 Feb 11. pii: 10.1007/s12185-021-03094.
    PubMed     Abstract available


  93. ONO R, Ashiarai M, Hirabayashi S, Mizuki K, et al
    Ruxolitinib for hematopoietic cell transplantation-associated hemophagocytic lymphohistiocytosis.
    Int J Hematol. 2021;113:297-301.
    PubMed     Abstract available


    January 2021
  94. LIU Z, Li Y, Shi C
    Monitoring minimal/measurable residual disease in B-cell acute lymphoblastic leukemia by flow cytometry during targeted therapy.
    Int J Hematol. 2021 Jan 27. pii: 10.1007/s12185-021-03085.
    PubMed     Abstract available


  95. KUMAMOTO T, Goto H, Ogawa C, Hori T, et al
    Correction to: FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Int J Hematol. 2021 Jan 23. pii: 10.1007/s12185-020-03077.
    PubMed    


  96. UENO T, Sugio Y, Ohta T, Uehara Y, et al
    Successful upfront cord blood transplantation for plasma cell leukemia in the first complete response after daratumumab therapy.
    Int J Hematol. 2021 Jan 22. pii: 10.1007/s12185-021-03082.
    PubMed     Abstract available


  97. SAKAMOTO H, Itonaga H, Sawayama Y, Kojima A, et al
    Allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma with HTLV-1-associated myelopathy.
    Int J Hematol. 2021 Jan 10. pii: 10.1007/s12185-020-03075.
    PubMed     Abstract available


  98. NAKAMURA F, Arai H, Nannya Y, Ichikawa M, et al
    Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
    Int J Hematol. 2021 Jan 5. pii: 10.1007/s12185-020-03074.
    PubMed     Abstract available


  99. FENG Y, Fu J
    Auer rods aid in the diagnosis of mixed phenotype acute leukemia.
    Int J Hematol. 2021 Jan 4. pii: 10.1007/s12185-020-03069.
    PubMed    


  100. QUANN KA, Redner RL
    The eyes have it: CNS leukemia presenting as optic neuritis.
    Int J Hematol. 2021 Jan 4. pii: 10.1007/s12185-020-03065.
    PubMed    


  101. NAKANO T, Kobayashi R, Matsushima S, Hori D, et al
    Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma.
    Int J Hematol. 2021 Jan 3. pii: 10.1007/s12185-020-03071.
    PubMed     Abstract available


  102. LIU F, Xue S, Zhang Y, Yang J, et al
    Clostridium perfringens sepsis in three patients with acute leukemia and review of the literature.
    Int J Hematol. 2021 Jan 2. pii: 10.1007/s12185-020-03060.
    PubMed     Abstract available


  103. XUE YJ, Wang Y, Jia YP, Zuo YX, et al
    The role of minimal residual disease in specific subtypes of pediatric acute lymphoblastic leukemia.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03063.
    PubMed     Abstract available


  104. CAI Y, Liu C, Guo Y, Chen X, et al
    Long-term safety and efficacy of imatinib in pediatric patients with chronic myeloid leukemia: single-center experience from China.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03042.
    PubMed     Abstract available


  105. KINOSHITA H, Okamura D, Sato T, Taji Y, et al
    Cytokeratin expression in therapy-related leukemia.
    Int J Hematol. 2021 Jan 1. pii: 10.1007/s12185-020-03062.
    PubMed    


  106. ITO F, Miura M, Fujioka Y, Abumiya M, et al
    The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
    Int J Hematol. 2021;113:100-105.
    PubMed     Abstract available


    November 2020
  107. SAITO T, Hatta Y, Hayakawa F, Takahashi T, et al
    Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
    Int J Hematol. 2020 Nov 23. pii: 10.1007/s12185-020-03032.
    PubMed     Abstract available


  108. HOSONO N, Ookura M, Araie H, Morita M, et al
    Clinical outcomes of gemtuzumab ozogamicin for relapsed acute myeloid leukemia: single-institution experience.
    Int J Hematol. 2020 Nov 20. pii: 10.1007/s12185-020-03023.
    PubMed     Abstract available


  109. INABA T, Tsukamoto T, Fujita N, Kuroda J, et al
    Auer-bodies in cellular components other than typical myeloblasts.
    Int J Hematol. 2020;112:605-606.
    PubMed    


  110. KANAYAMA T, Imamura T, Mayumi A, Soma E, et al
    Functional analysis of a novel fusion protein PAX5-KIDINS220 identified in a pediatric Ph-like ALL patient.
    Int J Hematol. 2020;112:714-719.
    PubMed     Abstract available


    October 2020
  111. IZUTSU K, Yamamoto K, Kato K, Ishikawa T, et al
    Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
    Int J Hematol. 2020 Oct 23. pii: 10.1007/s12185-020-03024.
    PubMed     Abstract available


  112. ZHANG XW, Shen X, Long WY, Xiao H, et al
    Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
    Int J Hematol. 2020 Oct 19. pii: 10.1007/s12185-020-03026.
    PubMed     Abstract available


  113. NAKATANI K, Matsuo H, Harata Y, Higashitani M, et al
    Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.
    Int J Hematol. 2020 Oct 17. pii: 10.1007/s12185-020-03015.
    PubMed     Abstract available


  114. AMITAI I, Abulafia AS, Raanani P, Lipton JH, et al
    Chronic myeloid leukemia in solid organ transplant patients: a case series.
    Int J Hematol. 2020 Oct 6. pii: 10.1007/s12185-020-03014.
    PubMed     Abstract available


  115. UCHIDA N, Matsumoto K, Sakura T, Hidaka M, et al
    Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
    Int J Hematol. 2020;112:510-523.
    PubMed     Abstract available


    September 2020
  116. LIU B, Li T
    Relapsed acute monocytic leukemia presenting as histiocytic morphology.
    Int J Hematol. 2020 Sep 20. pii: 10.1007/s12185-020-02995.
    PubMed    


  117. CORTES J, Podoltsev N, Kantarjian H, Borthakur G, et al
    Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia.
    Int J Hematol. 2020 Sep 20. pii: 10.1007/s12185-020-02994.
    PubMed     Abstract available


  118. OYA S, Morishige S, Ozawa H, Sasaki K, et al
    Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-PDGFRB fusion.
    Int J Hematol. 2020 Sep 19. pii: 10.1007/s12185-020-03006.
    PubMed     Abstract available


  119. YABE M, Morio T, Tabuchi K, Tomizawa D, et al
    Long-term outcome in patients with Fanconi anemia who received hematopoietic stem cell transplantation: a retrospective nationwide analysis.
    Int J Hematol. 2020 Sep 19. pii: 10.1007/s12185-020-02991.
    PubMed     Abstract available


  120. MOROZOVA EA, Olisova OY, Nikitin EA
    Cutaneous manifestations of B-cell chronic lymphocytic leukemia.
    Int J Hematol. 2020 Sep 5. pii: 10.1007/s12185-020-02978.
    PubMed     Abstract available


  121. OKAMOTO S, Ureshino H, Kimura S
    J-SKI will be able to elucidate whether the renal function recover or not after discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2020;112:429-430.
    PubMed    


    August 2020
  122. KIYOKI Y, Matsuoka R, Kaneta T, Nishikii H, et al
    (18)FDG-PET imaging and histopathology in neuroleukemiosis with acute myeloid leukemia.
    Int J Hematol. 2020 Aug 31. pii: 10.1007/s12185-020-02976.
    PubMed    


  123. KIHIRA K, Chelakkot VS, Kainuma H, Okumura Y, et al
    Close interaction with bone marrow mesenchymal stromal cells induces the development of cancer stem cell-like immunophenotype in B cell precursor acute lymphoblastic leukemia cells.
    Int J Hematol. 2020 Aug 30. pii: 10.1007/s12185-020-02981.
    PubMed     Abstract available


  124. HATTA Y, Hayakawa F, Yamazaki E
    JSH practical guidelines for hematological malignancies, 2018: I. leukemia-3. acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL).
    Int J Hematol. 2020 Aug 18. pii: 10.1007/s12185-020-02965.
    PubMed    


  125. SHIMODA K, Takahashi N, Kirito K, Iriyama N, et al
    JSH Practical Guidelines for Hematological Malignancies, 2018: I. Leukemia-4. Chronic myeloid leukemia (CML)/myeloproliferative neoplasms (MPN).
    Int J Hematol. 2020 Aug 11. pii: 10.1007/s12185-020-02964.
    PubMed    


  126. KUMAMOTO T, Goto H, Ogawa C, Hori T, et al
    FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Int J Hematol. 2020 Aug 6. pii: 10.1007/s12185-020-02962.
    PubMed     Abstract available


  127. KUROSAWA S, Yamaguchi H, Yamaguchi T, Fukunaga K, et al
    The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse.
    Int J Hematol. 2020;112:200-209.
    PubMed     Abstract available


  128. ANDO T, Sano H, Yokoo M, Kusaba K, et al
    Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor.
    Int J Hematol. 2020;112:249-253.
    PubMed     Abstract available


    July 2020
  129. SAITO M, Hasegawa H, Yamauchi S, Nakagawa S, et al
    A high-throughput detection method for the clonality of Human T-cell leukemia virus type-1-infected cells in vivo.
    Int J Hematol. 2020 Jul 29. pii: 10.1007/s12185-020-02935.
    PubMed     Abstract available


  130. LI YW, Xu YF, Hu W, Qian SX, et al
    Acute myeloid leukemia during pregnancy: a single institutional experience with 17 patients and literature review.
    Int J Hematol. 2020 Jul 18. pii: 10.1007/s12185-020-02938.
    PubMed     Abstract available


  131. HUANG Y, Zhang L
    Intracellular rod-like crystals in chronic lymphocyte leukemia.
    Int J Hematol. 2020 Jul 14. pii: 10.1007/s12185-020-02933.
    PubMed    


  132. CHILMI S, Nakahata S, Fauzi YR, Ichikawa T, et al
    Development of anti-human CADM1 monoclonal antibodies as a potential therapy for adult T-cell leukemia/lymphoma.
    Int J Hematol. 2020 Jul 12. pii: 10.1007/s12185-020-02939.
    PubMed     Abstract available


  133. HENZAN H, Takase K, Kamimura T, Mori Y, et al
    Correction to: Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Int J Hematol. 2020 Jul 8. pii: 10.1007/s12185-020-02932.
    PubMed     Abstract available


  134. ANDO T, Fujisawa S, Teshigawara H, Matsumura A, et al
    Computed tomography-defined sarcopenia: prognostic predictor of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study.
    Int J Hematol. 2020;112:46-56.
    PubMed     Abstract available


  135. MARKLIN M, Hagelstein I, Hinterleitner C, Salih HR, et al
    CD105 (endoglin) as risk marker in AML patients undergoing stem cell transplantation.
    Int J Hematol. 2020;112:57-64.
    PubMed     Abstract available


    June 2020
  136. HORIBE K, Morris JD, Tuglus CA, Dos Santos C, et al
    A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Int J Hematol. 2020 Jun 20. pii: 10.1007/s12185-020-02907.
    PubMed     Abstract available


  137. SEKI Y, Nagano O, Koda R, Morita S, et al
    Pathological findings suggesting vascular endothelial damage in multiple organs in chronic myelogenous leukemia patients on long-term tyrosine kinase inhibitor therapy.
    Int J Hematol. 2020 Jun 18. pii: 10.1007/s12185-020-02913.
    PubMed     Abstract available


  138. KIMURA SI, Fujita H, Handa H, Hiramoto N, et al
    Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group.
    Int J Hematol. 2020 Jun 18. pii: 10.1007/s12185-020-02921.
    PubMed     Abstract available


  139. URESHINO H, Kamachi K
    Vascular events may predict the prognosis of patients with chronic myeloid leukemia.
    Int J Hematol. 2020 Jun 12. pii: 10.1007/s12185-020-02889.
    PubMed    


  140. HENZAN H, Takase K, Kamimura T, Mori Y, et al
    Measurable residual disease after the first consolidation predicts the outcomes of patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.
    Int J Hematol. 2020 Jun 10. pii: 10.1007/s12185-020-02911.
    PubMed     Abstract available


  141. LUCIJANIC M, Krecak I
    Effect of age and comorbidities on the decline of glomerular filtration rate in chronic myeloid leukemia patients discontinuing tyrosine kinase inhibitors.
    Int J Hematol. 2020 Jun 9. pii: 10.1007/s12185-020-02915.
    PubMed    


  142. KANAYA M, Kondo T
    Diffuse alveolar hemorrhage during induction therapy for acute myeloid leukemia with inv(16)(p13.1q22).
    Int J Hematol. 2020 Jun 6. pii: 10.1007/s12185-020-02900.
    PubMed    


  143. ZHOU X, Zheng M, Wang Q, Aa J, et al
    Metabolomics analysis identifies lysine and taurine as candidate prognostic biomarkers for AML-M2 patients.
    Int J Hematol. 2020;111:761-770.
    PubMed     Abstract available


  144. TAKEDA R, Ishigaki T, Ohno N, Yokoyama K, et al
    Immunophenotypic analysis of cerebrospinal fluid reveals concurrent development of ATL in the CNS of a HAM/TSP patient.
    Int J Hematol. 2020;111:891-896.
    PubMed     Abstract available


    May 2020
  145. YOSHINO H, Nishiyama Y, Kamma H, Chiba T, et al
    Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood.
    Int J Hematol. 2020 May 4. pii: 10.1007/s12185-020-02885.
    PubMed     Abstract available


  146. SAWAKI A, Miyazaki K, Yamaguchi M, Takeuchi T, et al
    Genetic polymorphisms and vincristine-induced peripheral neuropathy in patients treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone therapy.
    Int J Hematol. 2020;111:686-691.
    PubMed     Abstract available


  147. URESHINO H, Shindo T, Sano H, Kubota Y, et al
    Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation.
    Int J Hematol. 2020;111:733-738.
    PubMed     Abstract available


  148. KAGEYAMA Y, Katayama N
    Ontogeny of human B1 cells.
    Int J Hematol. 2020;111:628-633.
    PubMed     Abstract available


    April 2020
  149. FUJITA H, Ishikawa Y, Yokoyama Y
    JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL).
    Int J Hematol. 2020 Apr 28. pii: 10.1007/s12185-020-02884.
    PubMed    


  150. OKAMOTO S, Ureshino H, Kawaguchi A, Miyazono M, et al
    Assessment of estimated glomerular filtration rate in patients with chronic myeloid leukemia following discontinuation of tyrosine kinase inhibitors.
    Int J Hematol. 2020 Apr 18. pii: 10.1007/s12185-020-02880.
    PubMed     Abstract available


  151. HINO M, Matsumura I, Fujisawa S, Ishizawa K, et al
    Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Int J Hematol. 2020 Apr 11. pii: 10.1007/s12185-020-02878.
    PubMed     Abstract available


  152. SUZUMIYA J, Takizawa J
    Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?
    Int J Hematol. 2020 Apr 6. pii: 10.1007/s12185-020-02867.
    PubMed     Abstract available


  153. SABURI M, Ogata M, Satou T, Soga Y, et al
    Prognostic implications of TdT expression in acute myeloid leukemia with an intermediate-risk karyotype.
    Int J Hematol. 2020 Apr 6. pii: 10.1007/s12185-020-02871.
    PubMed     Abstract available


    March 2020
  154. YAMAGUCHI H, Inokuchi K
    No sex-related difference in achievement of treatment-free remission following treatment with tyrosine kinase inhibitors in chronic myeloid leukemia.
    Int J Hematol. 2020 Mar 31. pii: 10.1007/s12185-020-02865.
    PubMed    


    February 2020
  155. OKURA E, Saito S, Natsume T, Morita D, et al
    Multiple heterogeneous bone invasions of B lymphoblastic lymphoma with the TCF3/PBX1 fusion gene: a case report.
    Int J Hematol. 2020;111:163-165.
    PubMed    


  156. POLPRASERT C, Takeda J, Niparuck P, Rattanathammethee T, et al
    Novel DDX41 variants in Thai patients with myeloid neoplasms.
    Int J Hematol. 2020;111:241-246.
    PubMed     Abstract available


  157. UEDA T, Jo T, Okada K, Arai Y, et al
    Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy.
    Int J Hematol. 2020;111:247-255.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: